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Inhibitory effect of la,25-dihydroxyvitamin D3 on the growth of the
renal carcinoma cell line. We studied the effect of vitamin D compounds
on the growth of the human renal carcinoma cell line (KU-2) and
discovered a receptor protein specific for the active form of vitamin D,,
la,25-dihydroxyvitamin D3. The KU-2 cell line was established from a
pulmonary metastasis of renal cell carcinoma in a patient with
hyperhemoglobinemia. The cells were tumorigenic in nude mice and
clonogenic in a soft agar culture.
Vitamin D3 derivatives suppressed proliferation of KU-2 cells in a
monolayer culture and also clonogenicity in a soft agar culture
dose—dependently. Of the vitamin D3 derivatives tested, la,25-
dihydroxyvitamin D3 was the most potent in inhibiting cell growth,
followed successively by la,24R,25-trihydroxyvitamin D,, 25-hydroxy-
vitamin D3, lcr-hydroxyvitamin D3 and 24R,25-dihydroxyvitamin D, in
that order. Analysis of the cell cycle phase of treated and non—treated
KU-2 cells revealed that the action of la,25-dihydroxyvitamin D, was
not phase—specific but simply extended the doubling time of the cells.
Radioreceptor assay and sucrose density gradient analysis of the
cytosol showed that KU-2 cells contained a 3.2S receptor protein to
which la,25-dihydroxyvitamin D, was specifically bound (Kd = 20.8
4.8 p, Nmax = 87 24 fmole/mg protein, 4000 molecules/cell). On the
other hand, the equilibrium dissociation constant of internalization of
I a,25-dihydroxyvitamin D3 (Kint) by intact KU-2 cells was 1.2 nM and
the internalizing capacity was 33 fmole/8 x 10 cells (2500
molecules/cell) in the 10% serum medium, which was the same as that
used in the growth study. This Kint value was very close to the
half-maximal dose in growth inhibition. Also the affinity of various
vitamin D3 derivatives for binding to the cytosot receptor in the KU-2
cells was closely related to the ability to inhibit growth of the cells.
These results indicate that the actions of vitamin D, derivatives in
inhibiting proliferation and clonogenicity of KU-2 cells are affected by
a receptor—mediated mechanism, and that the active form of vitamin D,
may be one of the regulatory factors affecting the proliferation and other
biological functions of renal carcinoma cells.
The importance of la,25-dihydroxyvitamin D3
[la,25(OH)2D3], the hormone of the parent vitamin D3, in
calcium metabolism, is well established. The major biological
function of la,25(OH)2D3 is to enhance intestinal calcium
transport and bone mineral mobilization by binding to a specific
cytosollnuclear receptor in those organs.
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Recently, much attention has been focused on the ubiquitous
distribution of similar la,25(OH)2D3 receptors. The receptors
have been found not only in such classical target organs of
vitamin D as intestine and bone, but also in kidney, parathy-
roid, skin, pancreas, spleen, brain, ovary, and hematopoietie
cells. It is also of great interest that the la,25(OH)2D3 receptors
are found not only in normal cells, but also in several tumor
cells. This suggests that the role of the hormone in biology
extends far beyond its classical role in mineral metabolism,
In 1981, Abe et al El] discovered that la,25(OH)7D3 inhibits
proliferation and induces differentiation of mouse myeloid
leukemia cells (Ml) into monocyte—macrophages. Subse-
quently, Honma et al [2] reported that in vivo administration of
la,25(OH)2D3 or 1 a-hydroxyvitamin D3 [1 a(OH)D3] consider-
ably prolongs the survival time of syngeneic SL strain mice and
athymic nude mice inoculated with Ml cells. The hormone also
inhibits proliferation of the receptor containing human myeloid
leukemia cells (HL-60) [3—5], human melanoma cells (Hs695T)
[6], and rat osteosarcoma cells 17]. More recently, Dokoh et al
[8] demonstrated that la,25(OH)2D3 inhibited the growth of
receptor—containing rat osteosarcoma cells (ROS17/2.8) in a
soft agar culture. Additionally, Wood et al [91 reported that the
topical application of la,25(OH)2D3 suppresses papilloma for-
mation induced by dimethylbenzanthracene (DMBA) and 12-0-
tetradecanoylphorbol-13-acetate (TPA) on mouse skin. These
results suggest the possibility that vitamin D compounds are
useful as anticancer therapeutic agents.
In 1976, Katsuoka et al [10, 11] established a cultured cell line
(KU-2) from a pulmonary metastasis of a renal cell carcinoma in
a patient with hyperhemoglobinemia. Renal carcinoma tumors
are known to be one of the least responsive tumors to anti-
cancer chemotherapy, Recent therapeutic trials utilizing inter-
feron or sex hormones have not yet achieved appreciable
clinical efficacy. Therefore, more effective therapeutic modali-
ties are needed to improve the prognosis of patients with renal
carcinoma. All of these newly discovered principles regarding
the relation of vitamin D3 derivatives to cancer suppression and
the presence of a receptor for la,25(OH),D3 in the kidney [12,
13] led us to examine whether renal carcinoma cells possess
similar la,25(OH)2D3 receptors and whether la,25(OH)2D3
inhibits the growth of such cells. The present study indicates
that the renal carcinoma cell line KU-2 has a receptor protein
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specific for la,25(OH)2D3 and that the hormone inhibits KU-2
cell proliferation by a receptor—mediated mechanism in vitro.
Methods
Cells and cell culture
The cultured cell line KU-2 was established by Katsuoka eta!
from a pulmonary metastasis of a renal cell carcinoma in a
patient with hyperhemoglobinemia, after temporary heterotrans-
plantation to a nude mouse in 1976 [10]. Electronmicroscopic
features of the KU-2 cells are similar to renal tubular cells [14].
KU-2 cells are anchorage—independent in soft agar cultures and
tumorigenic in nude mice [15]. The tumor from which KU-2
cells were derived has been maintained in nude mice so far and
is confirmed to produce erythropoietin [161. Cells were cultured
in Eagle's minimum essential medium containing 1.8 m Ca
supplemented with 10% heat—inactivated fetal bovine serum
(PBS, GIBCO, Grand Island, New York, USA), 0.292 gImliter
of L-glutamine, 100 g/mliter of streptomycin, and 100 U/muter
of penicillin G in a constant flow of 5% CO2 and 95% air with
humidity maintained at 37°C.
Effects of vitamin D3 derivatives on cell growth
Effects of la,25(OH)2D3 and its derivatives on growth of
KU-2 cells were studied in two different culture systems: a
monolayer culture and a soft agarose culture. In the latter
system [17], the feeder layer was made of 1 mliter of 0.5%
agarose in culture medium in a 35 mm petri dish. The cells
passaged two days before were detached from flasks by
trypsinization and 1 x i04 separated single cells were inocu-
lated in a culture layer made of 1 muter of 0.33% agarose.
Various concentrations of vitamin D3 derivatives were added to
both feeder and culture layers. The colony—forming rate was
calculated from the number of colonies which consisted of 20 or
more cells two weeks after inoculation.
The cell cycle of treated and non-treated cells was analyzed
as follows: the cells passaged 48 hr before were cultured in the
absence or presence of la,25(OH)2D3 for an additional 48 hr.
Then the cells were harvested by trypsinization and dehydrated
with graded concentrations of ethanol. The cells were stained
with 0.5% propidium iodide and analyzed by flowcytometry.
Cell populations in different cell cycle phases were determined
using the method of Slater et al [18].
Preparation of la,25(OH)2D3 receptor from KU-2 cells
A cytosol fraction of KU-2 cells was prepared as described
by Shiina et al [19]. Approximately 1 x 108 cells in the
exponential phase of growth were detached from petri dishes
with 0.1 M EDTA in Ca2 and Mg2-free phosphate buffered
saline (PBS), washed with PBS and pelletted three times by
centrifugation at 4°C. Then the cells were sonicated in a
hypertonic buffer which consisted of 0.3 M KC1, 2 m EDTA,
10 mM Tris/HC1, pH 7.4 and 0.5 m dithiothreitol (KETD-0.3).
The homogenate was centrifuged at 30,000 x g for 10 mm at
4°C. The resulting supernatant was centrifuged again at 225,000
x g for 60 mm at 4°C to yield a cytosol fraction. Protein
concentration in extracted cytosols was determined by the
method of Bradford [20].
For DNA-cellulose chromatography, a nuclear extract was
prepared by the method of Chandler et a! [21]. Approximately
3.6 x iO cells were harvested by trypsinization and resus-
pended in 5 mliter of serum—free culture medium. Then the cells
were incubated with 0.5 flM la,25(OH)2[3H]D3 for one hr at
37°C in a shaking water bath, and tritium—labeled cells were
rinsed three times in ice—cold PBS containing 1% PBS, followed
by centrifugation at 500 x g for five mm. The resulting pellet
was resuspended in 5 muter of a buffer containing 0.1 M KC1, 1
mM EDTA and 10 mrvi Tris/HCI (KET-0. 1), and homogenized
with Polytron (Kinematica, Switzerland). The homogenate was
centrifuged again at 1,100 x g for 15 mm, and the pellet was
resuspended in 0.5 mliter of a hypertonic buffer containing 0.3
M KC1, 1 m EDTA and 10 m Tris/HCI (KET-0.3), and
centrifuged again at 12,000 x g for five mm. The supematant
was diluted with a buffer containing no KC1 (KET-0) to 3 mliter
in volume and applied to DNA-cellulose chromatography.
Studies on la,25(OH)2[3H]D3 binding to the cytosol receptor
After the cytosol extract was diluted with KETD-0.3 buffer to
achieve a 1 mg protein/mliter in concentration, 0.5 mliter of the
cytosol solution (0.5 mg protein) was incubated with graded
concentrations of la,25(OH)2[3H]D3 (specific activity = 85
Ci/mmole, Amersham International plc., Bucks, United King-
dom) with or without 1,000-fold radioinert 1 a,25(OH)2D3 for 60
mm at 25°C. The bound la,25(OH)2[3H]D3 was separated by the
hydroxylapatite method described by Wecksler and Norman
[22]. The incubation was terminated by immersing the incuba-
tion tubes in an ice bath and by adding immediately 0.5 muter of
50% hydroxylapatite slurry suspended in 10 mrs Tris/HC1-0. 1 M
KC1, pH 7.5. The pellets were washed three times with 10 mM
Tris/HCI-0.5% Tnton-X, pH 7.5. The final washed pellet was
quantitatively extracted with 1 mliter of a mixed solvent of
methanol:chloroform (2:1) two times, and the solvent was
transferred to scintillation vials and evaporated to dryness. Six
mliter of the scintillation cocktail (ACS II, Amersham, United
Kingdom) was added to the vials and the radioactivity of the
samples was counted for two mm with an Aloka LC-900 liquid
scintillation counter.
The affinity of various vitamin D3 derivatives for the specific
la,25(OH)2D3 receptor was determined by a competitive recep-
tor assay. Aliquots of the cytosol (1 mg protein/muter) were
incubated with 0.25 nri 1c,25(OH)2[3H]D3, which was a satu-
rated concentration for the receptor in KU-2 cells, in the
presence or absence of graded concentrations of various D3
derivatives. The la,25(OH)2[3H]D3 bound to the receptor pro-
tein was extracted and counted.
The internalization of 1 a,25(OH)2[3H]D3 was studied as de-
scribed by Manolagas et al [23]. The cells in exponential phase
of growth were harvested, washed and suspended in Eagle's
MEM containing 10% FBS at 2 x iO cells/mliter. Aliquots of
0.4 mliter (8 x 106 cells) cell suspension were incubated with
graded concentrations of la,25(OH)2[3H]D3 with or without a
100-fold excess of radioinert la,25(OH)2D3 for four hr at 37°C in
a shaking water bath. The tubes were immersed in an ice bath
and the cells were washed with an isotonic buffer. Then the
cells were sonicated in KETD-0.3 buffer and ultracentrifuged as
previously described. Finally, the radioactivity in the superna-
tant was counted.
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Points and bars represent mean SD of two replicated determinationsFig. 1. Growth curves of KU-2 cells in a monolayer culture treated with
of quadriplicate experiments.Ia,25(OH).,D3. Symbols are: 0, control (0.1% ethanol); •, 1.2 nM
lts,25(OH)2D3; , 120 flM la,25(OH)2D3. Points and bars represent
mean SD of three replicated determinations of triplicate experiments,
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Sucrose density gradient analysis 6This analysis was performed as described elsewhere [24]. o0
Aliquots (500 iditer) of the cytosol preparation of KU-2 cells '6
were incubated with 1 mts la,25(OH)23HD3 in the presence or
absence of a 200-fold excess of radioinert lcs,25(OH)2D3. After
'a;
unbound radioligand was adsorbed by 50 p.liter of dextran- .0
coated charcoal, 200 p.liter of the tritirum—labeled cytosol was
layered onto a 4 to 20% discontinuous sucrose gradients pre-
pared in KETD-0.3 buffer. After centrifugation at 208,000 x g z
(average force) for 18 hr at 4°C, 100 piiter fractions were
collected from the top of the gradient tubes and radioassayed.
DNA-cellulose chromatography
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DNA-cellulose chromatography was performed as described
elsewhere [21]. The diluted nuclear extract (3 muter) was
applied to a 2.5 mliter DNA cellulose column equilibrated with
KET-0.05. After washing with KET-0.05, the labeled receptor
complex was eluted with a 20 mliter KET-0.05—KET-0.5 linear
gradient. All operations were performed at 4°C. One muter
fractions were collected at a flow rate of 1 mliter!min, and the
radioactivity of each fraction was counted. The salt concentra-
tion was determined with a conductivity meter.
Results
Effects on cell growth
la,25(OH)2D3 suppressed dose—dependent proliferation and
clonogenicity of KU-2 cells in the presence of 10% serum. In
the monolayer culture, the growth rate began to increase two
days after inoculation, and the cells grew linearly up to day five
or six. The average doubling time of the KU-2 cells was
increased from 21.0 hr to 22.4 hr and 26.9 hr when the cells were
exposed to 1.2 and 120 nM la,25(OH)2D3, respectively (Fig. 1).
In the soft agar culture, lix,25(OH)2D3 added to the semisolid
Fig. 3. Effect of the FBS concentration added to the medium on the
lcx,25(OH)2D,—induced suppression of KU-2 cell growth. The cells were
cultured in the 10% FBS medium (n), or in the 2% FBS medium ()
with graded concentrations of la,25(OH)2D3 for five days. Data are
mean SD (represented by bars) of two replicated determinations of
triplicate experiments,
medium also suppressed clonogenicity of KU-2 cells
dose—dependently. The clonogenicity was reduced to 89.6
2.8% of the control by adding 0.12 nM la,25(OH)2D3, to 65.0
5.0% by 1,2 nM, to 30.0 by 12 flM, and to 20.7 2.1% by
120 nM. la,25(OH)2D3 was the most potent in inhibiting
clonogenicity, followed successively by 1 a,24R,25-trihydroxy-
vitamin D3 [1 a,24R,25(OH)3D3], 25-hydroxyvitamin D3
[25(OH)D3], 1 a(OH)D3 and 24R,25-dihydroxy vitamin D3
[24R,25(OH)2D3] in that order (Fig, 2).
Suppression of KU-2 cell growth by la,25(OH)2D3 was
enhanced by reducing the serum concentration in the culture
medium to 2%. A half—maximal dose of la,25(OH)2D3 in
inhibiting growth in a monolayer culture was approximately 0.2
to 0.3 flM in the 2% serum medium (Fig. 3), whereas a
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Concentration of
la,25(OH)2D3 Plating efficiency, %
0 flM 45.7 6.7
1.2 48.6 6.1
12 50.4 3.1
120 45.8 5.5
half—maximal dose in the monolayer or the soft agar culture was
approximately 2 to 3 nM in the 10% serum medium (Figs. 2 and
3).
The subpopulations of untreated KU-2 cells in each cell cycle
phase were 57.5% in the 01 phase, 17.4% in the S phase and
25.1% in the G2 + M phase. DNA histograms of the KU-2 cells
treated with la,25(OH)2D3 for 48 hr showed a decrease in the S
and G2 + M peaks when each G 1 peak was adjusted to the same
peak height. The numbers of S phase cells decreased from
17.4% to 13.1 and 12.2% when 1.2 and 120 flM la,25(OH)2D3,
respectively, were added. Consequently, the relative numbers
of Gi and G2 + M phase cells to S phase cells increased. This
indicates that lcs,25(OH)2D3 increases the Gi and 02 cells, or
quiescent cells with the same DNA content, resulting in the
extension of the doubling time (Fig. 4).
To determine the cytotoxicity of la,25(OH)2D3, KU-2 cells
were pretreated with graded concentrations of the hormone for
72 hr. Then the cells were dispersed, inoculated in a soft agar
plate without la,25(OH)2D3, and incubated for 14 days. The
plating efficiency of the cells was not affected by the pretreat-
ment with 1.2 to 120 tIM gradations of la,25(OH)2D3 (Table 1).
Characterization of the receptor
Radioreceptor assay for the cytosol of KU-2 cells showed the
presence of a receptor protein to which la,25(OH)2D3 was
bound specifically. Scatchard plot analysis of the specific
la,25(OH)2D3 binding showed a low equilibrium dissociation
constant. Three replicates of the receptor assay and its
Scatchard plot analysis showed that the dissociation constant
(Kd) was 20.8 4.8 M and the binding capacity (Nmax) was 87
24 fmole/mg protein (mean SE), which means 4000 binding
sites/cell (Fig. 5).
To examine the role of the receptor in the mechanism of
action of la,25(OH)2D3—induced growth suppression, we mea-
sured the specific uptake of la,25(OH)2[3H]D3 by intake KU-2
cells under the same condition as used in the growth study.
Cells were monitored for the specific internalization of various
concentrations of la,25(OH)2[3H]D3 in the presence of 10%
serum in the culture medium. The results indicated that inter-
nalization by intact KU-2 cells was a specific and saturable
process. Scatchard plot analysis of the specific internalization
showed that the equilibrium dissociation constant for
la,25(OH)2D3 internalization (Kint) was 1.2 flM and the inter-
nalizing capacity was 33 fmole/8 x 106 cells (2500 mole-
cules/cell) (Fig. 6).
Sucrose density gradient analysis showed a sharp single peak
of a macromolecular radioligand sedimented at 3.2S which was
eliminated by adding 200-fold radioinert la,25(OH)2D3 (data not
shown).
Analysis for the receptor in nuclear extracts using DNA-
cellulose chromatography revealed the presence of a
la,25(OH)2D3—binding component which was adsorbed to DNA
at low ionic strength and was eluted at a concentration of 0.22
M KC1. This elution pattern is characteristic of the
la,25(OH)2D3 receptor previously reported [5, 13, 211 (Fig. 7).
Relationship between binding affinity and growth inhibition
A study of competition of various vitamin D3 derivatives for
the specific la,25(OH)2D3—binding sites in the KU-2 cytosol
showed that the concentrations of la,24R,25(OH)3D3,
25(OH)D3, la(OH)D3 and 24R,25(OH)2D3 required to displace
50% of the bound la,25(OH)2[3H]D3 were about 6-,375-, 700-
and 1,550-fold higher, respectively, than that of I cs,25(OH)2D3.
The ability of the vitamin D3 derivatives to inhibit proliferation
of KU-2 cells was closely related to their affinities for binding to
the la,25(OH)2D3 receptor in KU-2 cells (Fig. 8).
Discussion
The present study indicates that la,25(OH)2D3, even in
physiological concentrations, inhibits proliferation and
clonogenicity of KU-2 cells in vitro in a dose—dependent
manner. As stated in the introduction, recent reports have
demonstrated that la,25(OH)2D3 inhibits proliferation of sev-
eral tumor cell lines. The present report adds a renal carcinoma
cell line (KU-2) to the list of cells whose growth is suppressed
by la,25(OH)2D3. The suppressing effect of la,25(OH)2D3 on
KU-2 cells was confirmed in two different in vitro systems: a
monolayer culture and a soft agar culture. The rate of growth
suppression by la,25(OH)2D3 was higher in the latter than in
the former. Though this may be related in part to the time of
exposure to the vitamin, it may result alternatively from sup-
pression of a clonogenic factor or a decrease in the malignancy
of the cells.
The effect of liz,25(OH)2D3 in inhibiting growth of KU-2 cells
appears to be a function of a receptor—mediated mechanism.
KU-2 cells were found to possess a 3.2S cytosol protein to
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Fig. 4. DNA histograms of KU-2 cells treated with la,25(OH)2D.,. K'iJ-2
cells were incubated with la,25(OH)2D3 for 48 hr and analyzed by a
flowcytometry to determine DNA contents. Cell populations in each
cell cycle were counted from DNA histograms using the method
described by Slates et al [171.
Table 1. Clonogemcity of KU-2 cells pretreated with la,25(OH)2D3
KU-2 cells were treated with graded concentrations of la,25(OH)2D3
for 72 hr. Then the cells were dispersed, inoculated in a soft agar plate
without la,25(OH)2D3 and incubated for 14 days. Data are mean su
of two replicated determinations of triplicate experiments.
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Fig. 5. Saturation analysis of the receptor in KU-2
cytosol. Aliquots (500 z1iter) of the cytosol (1 mg
protein/muter) were incubated with graded
concentrations of la,25(OH)2[3H]D3 in the presence or
absence of a 1,000-fold molar excess of radioinert
la,25(OFI)2D3. Symbols are: •, total binding; 0,
non-specific binding; A, specific binding. Data are from
the means of triplicate experiments. Kd and Nmax were
derived from three replications of the saturation analysis
(mean SE). Kd = 20.8 1.8 psi. Nmax was calculated
as approximately 4000 molecules/cell. Nmax = 87 24
fmole/mg protein.
Fig. 6. Saturation analysis of the internalization of
la,25(OH)2['H]D3 by intact KU-2 cells in the medium
supplemented with 10% FBS. Aliquots of 0,4 muter
of cell suspension (8 x 106 cells, total) were
incubated with graded concentrations of
la,25(OH)2[3H]D3 in the presence of (0) or absence
(•) of a 100-fold molar excess of radioinert
I a,25(OFI)2D3 (left). Scatchard plot analysis of the
specific internalization (A) showed that the Kint was
1.2 nM and the internalized capacity was 33 fmole/8
x 106 cells (2500 molecules/cell) (right).
which la,25(OH)2D3 internalization (Kint) by intact KU-2 cells
was 1.2 nM in the same condition as was used in the growth
study, which was very close to the half-maximal dose of
la,25(OH)2D3 at approximately 2 n, to inhibit growth of KU-2
cells in the monolayer and soft agar cultures. Additionally, the
affinity of various vitamin D3 derivatives in binding to the
cytosol receptor of KU-2 cells was closely related to the ability
to inhibit proliferation of the cells. Frampton et al [25] reported
that a renal cell carcinoma cell line (Cob 293) has an
la,25(OH)2D3 receptor with a low binding capacity, but the
biological functions of the receptor were not described. In other
tumor cells, Mangelsdorf et al [5] reported that la,25(OH)2D3
inhibited growth of HL-60 cells by a receptor—mediated mech-
anism. They drew such a conclusion from evidence that the
Kint of HL-60 cells was virtually identical to the effective dose
in inducing 50% differentiation of the cells, and that a relatively
receptor—poor blast cell line of HL-60 was insensitive to the
induction of differentiation by la,25(OH)2D3. Dokoh et al [8]
have also demonstrated that 1 a,25(OH)2D3 inhibited growth of
receptor—containing rat osteogenic sarcoma cells (ROS 17/2.8)
more effectively than that of receptor—poor cells (ROS 24/1) in
a soft agar culture. This suggested that the growth inhibition by
la,25(OH)2D3 depends on the number of receptor binding sites
in the target cells. These results together with the present study
indicate the growth—inhibitory effects of la,25(OH)7D3 are
mediated by the specific la,25(OH)2D3 receptor. In contrast,
Chandler et al [21] recently reported that la,25(OHhD3 induced
the 24-hydroxylase activity of 25(OH)D3 in monkey kidney cells
(LLC-MK2) which are deficient in similar la,25(OH)2D3 recep-
tors with a high affinity. However, the same research group [26]
reported very recently that LLC-MK2 cells possessed the
immunologically same species (64,000 dalton) as the authentic
la,25(OH)7D3 receptor though its affinity was low, which
indicated that the receptor may be likewise involved in inducing
24-hdroxylation in these cells.
The Kd value of the cytosol receptor was much smaller than
the Kint value in KU-2 cells. Similar discrepancies between a
cytosol Kd and a cell Kint, or a concentration necessary for
growth suppression, are observed in some other cell lines [4—6,
8]. In case of HL-60 cells, the Kim' of the cells was reported to
be 5.4 nit's [5], while the cytosol Kd was 23 M [4]. These
differences were explained by the fact that the binding data
were obtained in cytosolic extracts in the absence of serum,
whereas the effects on cell growth or the Kinl were examined in
studies with serum—supplemented culture medium [8]. The
presence of serum lowers the concentration of
free—lct,25(OH)2D3 and interferes with the translocation proc-
ess of the hormone from the culture medium to the interior of
the cells. In contrast, Manolagas et al [23] reported that a Kd
was not different from a Kint in rat osteogenic sarcoma cells,
because both data were obtained in the serum—free medium.
Also the Kd value of the lct,25(OH)2D3 receptor of human
lymphocytes was reported to be almost identical to the half-
maximal dose in inhibiting of those proliferation [27, 28]. In the
present study on KU-2 cells, the Kim' was larger than the Kd,
whereas the internalizing and binding capacity were similar
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Fig. 7. DNA-cellulose chromatography of the la,25(OH)2[3H]D3 bind-
ing in the nuclear extracts of KU-2 cells. After samples were applied to
DNA-cellulose columns, fall—through radioactivity (-) was monitored
until a consistent baseline was established. Then DNA-binding compo-
nents were eluted with a linear KCI gradient (---) and the radioactivity
was counted. A la,25(OH)2[3H]D3-binding component was eluted at a
concentration of 0.22 M KC1.
(2500 and 4000 molecules/cell). Additionally, we studied growth
suppression by la,25(OH)2D3 in the 2% serum medium. The
half-maximal inhibition of cell growth in the 2% serum medium
was obtained by adding 0.2 to 0.3 n la,25(OH)2D3, which was
one-tenth the concentration in the 10% serum medium. Thus it
is likely that the discrepancy between the cytosolic Kd and the
cell Kint or the effective dose in inhibiting cell growth is due to
the presence of the serum.
It is not known how la,25(OH)2D3 affected the growth
kinetics of carcinoma cells. Analysis of the cell cycle of KU-2
cells treated with la,25(OH)2D3 showed that growth inhibition
by the vitamin resulted in a decrease of the cell population in
the S phase and in a relative increase of the cell population in
the Gi and G2 phases or non-cycling cells. This suggests that
growth inhibition by la,25(OH)2D3, unlike some anticancer
drugs with cytocidal effects, is non-specific to the cell cycle
phase, which results in the extension of doubling time or in
setting the cells at rest. Furthermore, the clonogenicity of KU-2
cells was not affected by preincubating the cells with
la,25(OH)2D3. This indicates that the vitamin inhibits prolifer-
ation of the cells in a cytostatic manner.
Of the several naturally occurring factors in regulating tumor
growth, sex steroids have been extensively studied as inhibitory
or stimulative in some particular tumors, such as prostatic
carcinoma and mammary carcinoma. These carcinoma cells
possess receptors for sex steroids. These steroids have already
been utilized as useful and indispensable therapeutic agents.
Renal cell carcinoma occurs more frequently in males than in
females, with a decrease in the male/female ratio in older
patients. It is known that some renal cell carcinomas also have
receptors for sex steroids [29, 30]. Chemotherapy using these
agents have been established since the middle 1960's as an
important therapeutic modality for advanced renal cell carci-
Growth
inhibition
la, 25(OH)203
la, 24R, 25(OH)3D3
.2
0
25(OH)D3
lu (OHIO3
24R, 25(OH}2D3
Fig. 8. A diagram representing the specfi city of various derivatives of
vitamin D3 in inhibiting KU-2 cell growth and the binding affinity of the
derivatives for the specific cytosol receptor of KU-2 cells. The growth
inhibition was expressed as the molar ratio of the vitamin D3 derivatives
to Ia,25(OH)2D3 required for suppressing clonogenicity of KU-2 cells
by 70% of the control. The binding affinity was expressed as the molar
ratio of the vitamin D3 derivatives to la,25(OH)2D3 required for 50%
displacement of la,25(OH)2[3H]D3 from the receptor.
noma. The overall response rate to the sex steroid therapy was
6 to 33% (mean, 15%) [3 1—33]. The result of this study confirms
that KU-2 is one of the cell lines in which lct,25(OH)2D3
exhibits growth inhibition by a receptor—mediated mechanism.
Also, the active metabolites of vitamin D suppressed
clonogenicity of KU-2 cells, which suggests that the vitamin
induces differentiation of the cells or suppresses the tumori-
genicity. These consequently indicate that the vitamin might be
one of the factors, like sex steroids, in modulating growth and
other biological functions of renal cell carcinoma, suggesting
further that vitamin D compounds might also be agents for the
treatment of renal cell carcinoma.
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